Orion Corporation
ORNAV.HEORNAV.HE · Stock Price
Historical price data
Overview
Orion Corporation is a century-old, publicly traded Finnish pharmaceutical leader with a dual-pillar strategy: developing proprietary drugs in CNS, oncology, and respiratory diseases, and operating a leading contract manufacturing (Fermion CDMO) business. Its major achievement is the global success of Nubeqa® (darolutamide) for prostate cancer, developed with Bayer, which anchors its growing oncology franchise. The company's vertically integrated operations, substantial pipeline, and resilient revenue model position it for sustainable growth in specialty pharma and the CDMO sector.
Technology Platform
Vertically integrated pharmaceutical development and manufacturing expertise, with deep capabilities in neuropharmacology, oncology targeted therapies, complex chemical synthesis (CDMO), and sustainable green chemistry.
Pipeline
112| Drug | Indication | Stage | Watch |
|---|---|---|---|
| Hydroxychloroquine + Placebo | Myocardial Infarction | Approved | |
| Levosimendan + Placebo | Heart Failure | Approved | |
| Methotrexate | Spondylarthropathies | Approved | |
| Dexmedetomidine | ICU Sedation | Approved | |
| Levosimendan + Placebo | Heart Failure | Approved |
Opportunities
Risk Factors
Competitive Landscape
In proprietary drugs, Orion competes with large pharma in oncology (e.g., Pfizer, J&J) and CNS. Its CDMO arm, Fermion, competes with global players like Lonza and Recipharm on technical expertise in complex synthesis. Vertical integration provides a unique competitive moat.
